button bars forest bayes pooled summary circles
 
DCR

mML - NA - all population metastatic/adv melanoma (mML) mML - (neo)adjuvant (NA) mML - NA - all population

versus interferon alpha
Ipilimumab (10 mg/kg) vs. interferon alpha 1
ipilimumab alone vs. interferon alpha 1
versus Ipilimumab (10 mg/kg)
nivolumab alone vs. Ipilimumab (10 mg/kg) 1
versus nivolumab alone
nivolumab plus ipilimumab vs. nivolumab alone 1
versus placebo
Ipilimumab (10 mg/kg) vs. placebo 1
nivolumab alone vs. placebo 1
nivolumab plus ipilimumab vs. placebo 1
pembrolizumab alone vs. placebo 1

mML - NA - PDL1 positive metastatic/adv melanoma (mML) mML - (neo)adjuvant (NA) mML - NA - PDL1 positive

versus placebo
pembrolizumab alone vs. placebo 1

mML - L1 - all population metastatic/adv melanoma (mML) mML - 1st line (L1) mML - L1 - all population

versus ipilimumab alone
nivolumab alone vs. ipilimumab alone 1
nivolumab plus ipilimumab vs. ipilimumab alone 2
versus ipilimumab followed by nivolumab
nivolumab followed by ipilimumab vs. ipilimumab followed by nivolumab 1
versus nivolumab alone
nivolumab plus ipilimumab vs. nivolumab alone 1
relatlimab plus nivolumab vs. nivolumab alone 1
versus Standard of Care (SoC)
tremelimumab vs. Standard of Care (SoC) 1

mML - L1 - BRAF mutant metastatic/adv melanoma (mML) mML - 1st line (L1) mML - L1 - BRAF mutant

versus ipilimumab alone
nivolumab plus ipilimumab vs. ipilimumab alone 1
versus placebo plus SoC
atezolizumab plus SoC vs. placebo plus SoC 1

mML - L1 - BRAF wild metastatic/adv melanoma (mML) mML - 1st line (L1) mML - L1 - BRAF wild

versus dacarbazine
nivolumab alone vs. dacarbazine 1
versus ipilimumab alone
nivolumab plus ipilimumab vs. ipilimumab alone 1
versus pembrolizumab alone
atezolizumab plus cometinib vs. pembrolizumab alone 1 0.91

mML - L2 - all population metastatic/adv melanoma (mML) mML - 2nd line (L2) mML - L2 - all population

versus gp100
ipilimumab alone vs. gp100 1
ipilimumab plus gp100 vs. gp100 1
versus ipilimumab alone
Ipilimumab (10 mg/kg) vs. ipilimumab alone 1 1.19
ipilimumab plus gp100 vs. ipilimumab alone 1
pembrolizumab (10mg/kg) vs. ipilimumab alone 1
pembrolizumab (10mg/kg) 2 weeks vs. ipilimumab alone 1
versus placebo plus SoC
ipilimumab plus SoC vs. placebo plus SoC 1 1.15
versus Standard of Care (SoC)
nivolumab alone vs. Standard of Care (SoC) 1
pembrolizumab (10mg/kg) vs. Standard of Care (SoC) 1
pembrolizumab (2mg/kg) vs. Standard of Care (SoC) 1

mML - L2 - BRAF mutant metastatic/adv melanoma (mML) mML - 2nd line (L2) mML - L2 - BRAF mutant

versus placebo plus SoC
pembrolizumab plus SoC vs. placebo plus SoC 1

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons